Envoy Medical Q3 revenue falls to $56K; FDA OKs pivotal trial for Acclaim CI

Envoy Medical, Inc.

2024-Q3 EPS reported -$1.03 revenue$183,000

Net revenues $56K for Q3 2024, down 30% from $80K in Q3 2023; nine-month revenues $183K, down 17%.
Cash and cash equivalents $4.4M as of Sep 30, 2024, with R&D expenses up 47% to $2.8M due to clinical prep for Acclaim CI.
FDA approved initiation of pivotal clinical study for fully implanted Acclaim Cochlear Implant (investigational, Breakthrough Device).
AMA CPT Editorial Panel approved Category III CPT codes for totally implantable middle ear hearing devices (support for Esteem FI-AMEI reimbursement).
Bipartisan House and Senate bills introduced to change CMS classification for fully implanted middle ear hearing devices for Medicare coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.